Phase 2 Dose-finding IMU-838 for Ulcerative Colitis
Status:
Active, not recruiting
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding
study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy
with an option for open-label treatment extension in moderate-to-severe ulcerative colitis
(CALDOSE-1).